PROCEPT BioRobotics Corporation — Earnings Quality Grade C
PRCT · Healthcare
Some red flags
Screening Summary
管理层信号
Financial Trends
Revenue & Net Income ($B)
Margins (%)
18-Point Screening
Revenue Quality
DSO 99 days, change -37 days YoY
AR growth 0.0% vs revenue growth 37.2%
Revenue 37.2%, CFFO 50.6%. Cash follows revenue
Expense Quality
Inventory 25.9% vs COGS 28.0%. Normal
CapEx growth 112.2% is >2x revenue growth 37.2%
SG&A/Gross Profit = 116.6%, exceeds 70%
Gross margin 63.7%, change +2.6pp. Stable
Cash Flow Quality
CFFO/NI = 0.51. Below 1.0
FCF is negative ($-0.1B)
Accruals ratio = -9.2%. Low accruals
Cash $0.3B covers debt $0.1B
Balance Sheet Health
Goodwill+Intangibles $0.0B = 0% of equity. Manageable
Interest coverage = -29.0x (<2x). Financial stress
Other assets 61.9% vs revenue 37.2%. Normal
No write-off data
Acquisition Risk
FCF after acquisitions negative for 3 years
Small-cap context: A single acquisition on a small balance sheet can trip serial-acquirer logic.
Goodwill+Intangibles change -24% YoY. Normal
Manipulation Score
M-Score = -2.69 (< -2.22). Unlikely manipulator
Beneish M-Score
Altman Z-Score
Generated from public financial data using forensic accounting frameworks. Not investment advice. Data: Yahoo Finance · 2026-04-25